The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).
 
Jennifer Rachel Eads
Consulting or Advisory Role - Novartis; Oxigene; Portola Pharmaceuticals; Saatchi Wellness
Research Funding - AstraZeneca; Bayer; HealthCare Pharmaceuticals; Merck; Novartis
Travel, Accommodations, Expenses - Amgen
 
Paul J. Catalano
Research Funding - Lilly/ImClone
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Consulting or Advisory Role - Celgene; ipsen
Research Funding - Bristol-Myers Squibb (Inst); EpicentRx (Inst); Genentech/Roche (Inst); Newlink Genetics (Inst); Pharmaceutical Research Associates (Inst); Polaris (Inst); Tercica (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
David S. Klimstra
No Relationships to Disclose
 
Zheng Zhang
No Relationships to Disclose
 
Daniel Rubin
Research Funding - GE Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Stanford University (Inst)
 
Andrei Iagaru
Research Funding - Bayer (Inst); GE Healthcare (Inst); Piramal Life Science (Inst); Sanofi (Inst)
 
Terence Z. Wong
Consulting or Advisory Role - Philips Healthcare
Travel, Accommodations, Expenses - Philips Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - BBI Healthcare; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer